AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01939366 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cebranopadol 600 µg
Description: Participants randomized to 600 μg cebranopadol will start with 200 μg per day and increase to 400 µg per day on day 4 and to 600 µg on day 7, thereafter they will remain on 600 µg per day.
Study NCT01939366 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pregabalin
Description: Stepwise titration from 75 mg twice a day to 300 mg twice a day over 2 weeks.
Study NCT01939366 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Matching Placebo
Description: Placebo will be matched to pregabalin and cebranopadol.
Study NCT04349956 — intervention group
Intervention type: DRUG
Intervention: UBX0101 or placebo
Description: This is an observational study. No intervention is administered.
Study NCT01320592 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PD0332991
Study NCT01320592 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Study NCT00237809 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Retraining Placebo
Description: Cognitive retraining therapy (CRT) control
Study NCT03748459 — intervention group
Intervention type: OTHER
Intervention: Closure with Permanent Suture
Description: Skin closure with permanent suture (prolene) (6-0 polypropylene) in open rhinoplasty.
Study NCT03748459 — intervention group
Intervention type: OTHER
Intervention: Closure with Resorbable Suture
Description: Skin closure with Resorbable Suture (5-0 fast absorbing plain gut) in open rhinoplasty.
Study NCT01673204 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT01734967 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: needle based CLE
Description: EUS-nCLE will be performed after EUS identification of the pancreatic tumor / lymph node / liver metastasis:~The confocal microprobe will be preloaded in a 19G FNA needle as previously described and advanced into the lesion under EUS guidance.~nCLE examination will follow after the intravenous administration of the contrast agent (2.5 ml fluorescein 10%).~Image data will be stored digitally for offline analysis.
Study NCT01734967 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: EUS-FNA
Description: Endoscopic ultrasound (EUS) is an established tool in pancreatic masses used both for diagnosis, but also for staging purposes. Additionally, EUS enables guided fine needle aspiration (FNA), which is currently recommended as the first-line procedure whenever a pathological diagnosis is required.
Study NCT01787435 — intervention group
Intervention type: DRUG
Intervention: Risk of asthma in offspring
Description: Exposure to PPI or H2RA, respectively during pregnancy~No exposure to acid suppressing drugs during pregnancy
Study NCT04778696 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: PASO Pacemapping
Description: Using the PASO pacemapping visualisation module of CARTO3
Study NCT04778696 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Pacemapping
Description: without visualisation in 3D mapping
Study NCT04087967 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Decitabine plus HAAG regimen
Description: Decitabine:20mg/m2/d,d1\~5, intravenous infusion; Homoharringtonine:1mg/d,d3\~16,intravenous infusion; Aclarubicin:10mg/d, d3\~d10, intravenous infusion; Cytarabine:10mg/m2,q12h,d3-16, subcutaneous injection;~Granulocyte colony-stimulating factor (G-CSF):~50-300μg/d (when WBC counts are less than 20×10\^9/L ),subcutaneous injection;
Study NCT04087967 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Idarubicine plus Cytarabine regimen
Description: Idarubicine :12mg/m2, d1-3, intravenous infusion; Cytarabine :100mg/m2, d1-7, 24-hours continuous intravenous infusion
Study NCT03396406 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Pulsed radiofrequency (PRF)
Description: received PRF at 42°C for 8 minutes followed by CRF at 60°C for 270s
Study NCT03396406 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: thermocoagulation
Description: received sole CRF at 70°C for 270 s
Study NCT00759551 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azilsartan
Description: Azilsartan 2.5 mg, tablets, orally, once daily and olmesartan placebo-matching capsules and tablets, orally, once daily for up to 8 weeks.
Study NCT00759551 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azilsartan
Description: Azilsartan 5.0 mg, tablets, orally, once daily and olmesartan placebo-matching capsules and tablets, orally, once daily for up to 8 weeks.
Study NCT00759551 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azilsartan
Description: Azilsartan 10 mg, tablets, orally, once daily and olmesartan placebo-matching capsules and tablets, orally, once daily for up to 8 weeks.
Study NCT00759551 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azilsartan
Description: Azilsartan 20 mg, tablets, orally, once daily and olmesartan placebo-matching capsules and tablets, orally, once daily for up to 8 weeks.
Study NCT00759551 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azilsartan
Description: Azilsartan 40 mg, tablets, orally, once daily and olmesartan placebo-matching capsules and tablets, orally, once daily for up to 8 weeks.
Study NCT00759551 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Azilsartan placebo-matching tablets, orally, once daily and olmesartan placebo-matching capsules, orally, once daily for up to 8 weeks.
Study NCT00759551 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Olmesartan
Description: Azilsartan placebo-matching tablets, orally, once daily and olmesartan 20 mg, capsules, orally, once daily for up to 8 weeks.
Study NCT05610228 — intervention group
Intervention type: OTHER
Intervention: NO intervention
Description: No intervention
Study NCT03733171 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: diluted epinephrine
Description: diluted epinephrine was injected in 1-2 ml by multiple injections into and circumferentially around the ulcer until bleeding stopped using a 25-G retractable, standard sclerotherapy needle
Study NCT03778073 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cosibelimab
Description: Intravenous infusion on Days 1 and 15 of every 28-day cycle or only on Day 1 of every 28-day cycle
Study NCT03778073 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cosibelimab + Ublituximab + Bendamustine combination
Description: Cosibelimab (Intravenous infusion):~Cycle 1-6 Days 1\&15, Cycles 7-12 Day 1, Cycles 15-24 Day 1 every 3 cycles;~Ublituximab (Intravenous infusion):~Cycles 1-6 Day 1, Cycles 9-24 every 3 Cycles;~Bendamustine (Intravenous infusion):~Cycle 1 Days 2\&3, Cycles 2-6 Days 1\&2.
Study NCT03778073 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cosibelimab + Ublituximab + Bendamustine combination
Description: Cosibelimab (Intravenous infusion):~Cycle 1-12 Day 1, Cycles 15-24 Day 1 every 3 cycles;~Ublituximab (Intravenous infusion):~Cycles 1-6 Day 1, Cycles 9-24 every 3 Cycles;~Bendamustine (Intravenous infusion):~Cycle 1 Days 2\&3, Cycles 2-6 Days 1\&2.
Study NCT03165825 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Transforaminal Epidural Steroid Injection with Dexamethasone
Description: Transforaminal Epidural Steroid Injection with Dexamethasone
Study NCT03165825 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Interlaminar Epidural Steroid Injection with Betamethasone
Description: Interlaminar Epidural Steroid Injection with Betamethasone
Study NCT02207140 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: HOWARU Restore
Study NCT01730924 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Pulmonary vein isolation using contact force sensing catheter
Study NCT01943006 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hirudoid cream 0.3 % Mucopolysaccharide polysulfate
Description: Hirudoid cream
Study NCT01943006 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo cream without active substance
Study NCT02010645 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eltrombopag
Description: Starting dose of Eltrombopag is 100 mg by mouth daily for each 28 day cycle. East Asians will start at 50 mg by mouth daily for each 28 day cycle.
Study NCT02010645 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Decitabine
Description: Starting dose of Decitabine is 20 mg/m2 by vein on Days 1-5 for each 28 day cycle.
Study NCT03733171 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: hemoclips
Description: diluted epinephrine was injected followed by application of hemoclips
Study NCT05452395 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Post-acute care
Description: A personalized care program, focusing on managing geriatric syndromes and improving functional performances.~Strength training, activities of daily living (ADL) and instrumental activities of daily living (IADL) practice, basic mobility training, reconditioning exercise, and home environment assessment and modification.
Study NCT02207140 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: HOWARU Restore
Study NCT02173990 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aflibercept-FOLFIRI
Description: Aflibercept : 4 mg/kg, IV over 1 h on Day 1~FOLFIRI :~* Irinotecan 180 mg/m² IV infusion in 500 mL D5W (5% Dextrose in Water solution) over 90 minutes and dl leucovorin\* 400 mg/m² IV infusion over 2 hours, at the same time, in bags using a Y-line, followed by :~* 5-FU 400 mg/m² IV bolus given over 2-4 minutes, followed by :~* 5-FU 2400 mg/m² continuous IV infusion in 500 mL over 46-hours.~  * \*400 mg/m² of leucovorin expressed in dl racemic. When the l-isomer form is used the dose should be divided by 2, i.e. 200 mg/m²
Study NCT03560154 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Whole Body Vibration Training
Description: whole body vibration application will be performed in the range of 25-40 Hz, with amplitude 1-2 mm, 30-60 seconds (30-45 seconds) application and resting times of 60 seconds, 2-5 sets each session. Also, as a home program; respiratory exercises will be taught every day of the week for 10 minutes a day.
Study NCT01722552 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: adherence feedback
Study NCT01722552 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: standard of care
Study NCT03984916 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Hesperidin Pharma
Description: Two capsules with 250 mg of sweet orange extract with a mixture of hesperidin isomers -S and -R.
Study NCT03984916 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Hesperidin Pharma_M
Description: Two capsules with 250 mg of sweet orange extract each with a mixture of hesperidin isomers -S and -R and micronized.
Study NCT03984916 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Cardiose
Description: Two capsules with 250 mg of sweet orange extract each with more than 90% of hesperidin as isomer -S and micronized.
Study NCT01728454 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo matching capsules, orally, once daily for 18 weeks.
Study NCT01728454 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Telapristone acetate
Description: Telapristone acetate capsules, orally once daily for 18 weeks.
Study NCT02763605 — intervention group
Intervention type: OTHER
Intervention: no intervention
Study NCT01278966 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: The Modified Atkins Diet
Description: The Modified Atkins Diet; 10 g carbohydrate per day and a high fat intake
Study NCT01882036 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Gastric Bypass w/ matched hypocaloric diet
Description: Roux en Y Gastric Bypass with Hypocaloric liquid diet for 10 days
Study NCT01882036 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Hypocaloric diet
Description: Hypocaloric liquid diet for 10 days
Study NCT02155660 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Benralizumab Arm A
Description: Benralizumab subcutaneously on study week 0 until study week 48 inclusive
Study NCT02155660 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Benralizumab Arm B
Description: Benralizumab subcutaneously on study week 0 until study week 48 inclusive
Study NCT02155660 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Benralizumab Arm C
Description: Benralizumab subcutaneously on study week 0 until study week 48 inclusive
Study NCT02155660 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Benralizumab subcutaneously on study week 0 until study week 48 inclusive
Study NCT04384952 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Parent-administered reading therapy.
Description: Parent-administered reading therapy program: 15min each day, 5 days a week during 6 weeks during the summer break. Repeted reading with feedback from the parent and time control.
Study NCT04384952 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Dyslexic's Holiday Workbook
Description: Use of a special Dyslexic's holiday book, no parent-guided training.
Study NCT00758394 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Fluoride
Description: Brush two times a day for 4 days.
Study NCT00758394 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Triclosan/Fluoride
Description: Brush two times daily for 4 days
Study NCT00758394 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Triclosan/Fluoride
Description: Brush twice daily for 4 days
Study NCT00396266 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: G-CSF Plus Plerixafor
Description: Participants underwent mobilization with G-CSF 10 µg/kg/day for 4 days, administered by subcutaneous injection (SC) injection each morning. On the evening of Day 4, participants received a dose of plerixafor 240 µg/kg, administered by SC injection. On Day 5, participants returned to the clinic and received a morning dose of G-CSF 10 µg/kg and underwent apheresis approximately 10 to 11 hours after the dose of plerixafor (within 60 minutes after administration of G-CSF). Participants continued to receive an evening dose of plerixafor followed the next day by a morning dose of G-CSF and apheresis for up to a maximum of 5 aphereses or until ≥ 5\*10\^6 CD34+ cells/kg were collected.
Study NCT03862729 — intervention group
Intervention type: PROCEDURE
Intervention: Minimally invasive surgery
Description: Intracranial hematoma will be removed by intraoperative stereotactic computer tomography-guided endoscopic surgery, or surgical aspiration followed by alteplase clot irrigation (1·0 mg every 8 h for up to nine doses). CTA will be performed before operation in all the patients for intraoperative navigation, and the minimally invasive surgery will be performed within 24 hours after intracerebral hemorrhage onset.
Study NCT03862729 — intervention group
Intervention type: PROCEDURE
Intervention: conventional treatment
Description: Conventional treatment includes medical treatment and conventional craniotomy.
Study NCT03776331 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Flow mediated dilation
Description: Measurement of the change in the vasodilatative reserve of the brachial artery
Study NCT03820804 — intervention group
Intervention type: OTHER
Intervention: Diet
Description: A specific dietary treatment for patients with Phenylketonuria.
Study NCT03820804 — intervention group
Intervention type: DRUG
Intervention: Sapropterin
Description: A pharmacological treatment for patients with Phenylketonuria, used alone or in combination with dietary treatment.
Study NCT01297621 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: reduction mammaplasty
Description: conventional reduction mammaplasty
Study NCT01297621 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: control
Description: follow up, questionnaire responses
Study NCT02781662 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Pharmacist Home-Visit
Study NCT03506464 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Myofascial Release Technique
Description: The same described in the arm description
Study NCT04417816 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise training intervention with ultrasound induced adipose tissue cavitation
Description: Exercise training intervention with ultrasound induced adipose tissue cavitation
Study NCT04417816 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Exercise training intervention without ultrasound induced adipose tissue cavitation
Description: Exercise training intervention with ultrasound induced adipose tissue cavitation
Study NCT03638388 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Dry needling (DN)
Description: One to three filament needles (similar to an acupuncture needle) with no medication will be inserted into the tender area of my muscle. The needles will be repositioned a few times to make the muscle twitch. After several twitches occur, the researcher will leave the needles as they are, and the subject will sit in a chair without moving my arms or head, for 10 minutes. After 10 minutes the needles are removed and discarded.
Study NCT03638388 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Dry needling with intramuscular electrical stimulation (DNES)
Description: One to three filament needles (similar to an acupuncture needle) with no medication will be inserted into the tender area of the muscle. The needles will be repositioned a few times to make the muscle twitch. After several twitches occur, the researcher will leave the needles as they are, and attach alligator clips to the needles to provide electrical stimulus for 10 minutes while the subject sits in a chair without moving arms or head. After 10 minutes, the electrical stimulus will be turned off and detached, and the needles removed and discarded.
Study NCT00465894 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Extended Release Tolterodine LA
Description: Tolterodine LA 4 mg once daily for 52 weeks. At 12 Weeks, the subjects were offered the addition of the alternative therapy with follow-up at 24 and 52 weeks
Study NCT00465894 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intra Vaginal Estradiol Cream
Description: 17-B estradiol cream 0.5 grams nightly for 6 weeks then two times weekly for 46 weeks. At 12 Weeks, the subjects were offered the addition of the alternative therapy with follow-up at 24 and 52 weeks.
Study NCT03725709 — intervention group
Intervention type: PROCEDURE
Intervention: spinal anesthesia
Description: Plan to enroll 120 Type 2 diabetes and 120 non-diabetes patients with received spinal anesthesia.Blood will be collected at time point of pre-anesthesia 10 minutes and CSF samples will be collected at time point during spinal anesthesia induction. Blood will be collected, drawn into EDTA-coated tube.
Study NCT04144257 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [F-18]PBR06
Description: PET radiopharmaceutical. Subjects will undergo \[F-18\]PBR06-PET (microglial activation).
Study NCT04144257 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [C-11]Methylreboxetine
Description: PET radiopharmaceutical. Subjects will undergo \[C-11\]MRB-PET (norepinephrine transporter binding).
Study NCT01231620 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zanamivir
Description: Zanamivir aqueous solution, 10 mg/mL, will be provided as a single use, sterile clear, colorless preparation in 20 mL clear glass vials.
Study NCT01231620 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo to match zanamivir
Description: Placebo to match IV zanamivir will be provided as a normal saline solution of a matched volume.
Study NCT01231620 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oseltamivir
Description: Oseltamivir will be provided as over-encapsulated 75 mg capsules.
Study NCT01231620 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to match oseltamivir
Description: Placebo to match oral oseltamivir will be provided as capsules with a common excipient of appropriate quality.
Study NCT02833142 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIIB033 (opicinumab)
Study NCT01941160 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Lacidofil® STRONG
Description: Lacidofil® STRONG capsule twice daily
Study NCT01941160 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo capsule twice daily
Study NCT05737927 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Glucose 8 g coated beads (47% w/w)
Description: After an overnight fasting of about 10 hours, the subjects were administered 8 g glucose of the coated Glucose beads formulation starting at 8:00 (time 0; administration time was staggered beginning at 8:00 for the first group of subjects) in sitting position.
Study NCT05737927 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Glucose 12 g coated beads (47% w/w)
Description: After an overnight fasting of about 10 hours, the subjects were administered 12 g glucose of the coated Glucose beads formulation starting at 8:00 (time 0; administration time was staggered beginning at 8:00 for the first group of subjects) in sitting position.
Study NCT02271945 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MEDI-551 12 mg/kg
Description: Participants will receive intravenous (IV) infusion of MEDI-551 12 mg/kg on Days 1 and 8 of Cycle 1 and Day 1 of Cycle 2 through Cycle 13
Study NCT02271945 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MEDI0680 2.5 mg/kg
Description: Participants will receive IV infusion of MEDI0680 2.5 mg/kg on Days 2 and 15 of Cycle 1 and Days 1 and 15 of Cycle 2 through Cycle 13.